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Uterine tumors resembling ovarian sex-cord tumors
(UTROSCTs) are rare uterine neoplasms that were originally
described in 1976 [1]. They are divided into typical endometrial
stromal tumors with focal sex-cord-like differentiation (Group I)
and tumors composed predominantly of sex-cord-like elements
(Group II). Group I tumors often recur, whereas Group II tumors are
generally benign, with some exhibiting metastasis and recurrence
[2e5]. UTROSCTs are polyphenotypic, coexpress markers of
epithelial, myoid, and sex-cord lineages, and contain hormone re-
ceptors. However, the efﬁcacy of hormonal therapy remains un-
known due to the rarity of UTROSCTs. The effectiveness of high-
dose progestin and aromatase inhibitors for endometrial stromal
sarcoma is well known, with these agents being used to treat Group
I tumors. However, hormonal therapy for Group II tumors has not
been reported.
A 62-year-old woman with a Group II UTROSCT developed
pelvic lymph node recurrence 23 years after undergoing hyster-
ectomy for the primary tumor. Computed tomography revealed a
solid tumor, 14.0 cm 10.2 cm in maximum diameter, that
appeared to invade the left pelvic wall (Figure 1A). Pathological
examination of the primary uterine tumor revealed several pat-
terns of sex-cord-like elements inﬁltrating the uterine myome-
trium (Figures 1C and 1D). Tumor cells with scant eosinophilic or
abundant pale cytoplasm were arranged in anastomosing* Corresponding author. Division of Gynecologic Oncology, National Hospital
Organization, Hokkaido Cancer Center, 4-2, Kikusui, Shiroishi-Ku, Sapporo 003-
0804, Japan.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).trabeculae (Figure 1E), small nests (Figure 1F), and cords. Nuclear
ﬁndings with mild atypia were uniform. Immunohistochemical
examination of the recurrent tumor revealed that the neoplastic
cells were negative for keratin, CD99, and melan-A, focally pos-
itive for calretinin, CD56, CD10, and h-caldesmon, and diffusely
positive for vimentin, desmin, and a-smooth muscle actin. The
patient initially received letrozole (an aromatase inhibitor) at
2.5 mg daily and medroxyprogesterone acetate at 600 mg daily,
because immunohistochemical studies revealed that her tumor
cells were estrogen- and progesterone-receptor positive. These
hormonal agents were stopped after 3 months, because no
response was observed (Figure 1B). She then underwent embo-
lization of the feeding arteries of the tumor, followed by cyto-
reductive surgery due to the appearance of pleural effusion and
deep vein thrombosis. Pathological examination of the recurrent
pelvic tumor revealed morphological ﬁndings similar to the
primary uterine tumor. Although the tumor was incompletely
resected, the patient was alive and asymptomatic 20 months
postoperation. The differential diagnoses were UTROSCT,
epithelioid leiomyosarcoma, perivascular epithelioid cell
neoplasm, and endometrioid adenocarcinoma. No endometrial
stromal sarcoma features were seen in either the entire primary
or recurrent specimen. Considering the morphological charac-
teristics, diverse phenotypic proﬁle, and indolent clinical course,
the deﬁnitive diagnosis was recurrence of Group II UTROSCT.
There are few published reports of metastatic or recurrent
Group II tumors. Previous reports described metastases to the
ovary [2], omentum [2], lymph nodes [3], and epiploic appendix
[3], with only two cases of recurrent Group II tumors reported
(Table 1) [4,5]. With the development of minimally invasive sur-
gery, conservative management in young women with UTROSCT
might be expected; however, the long-term outcomes of conser-
vative management of Group II UTROSCTs have not been reported,
and we do not believe that conservative management is clinically
feasible at present.
Although a hysterectomy might not always be necessary, path-
ological ﬁndings obviously affect clinical outcomes. UTROSCTs with
inﬁltrating growth patterns are apparently more likely to recury Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. (A) CT image showing a large solid mass occupying the pelvic cavity and seemingly invading the left pelvic wall. (B) CT image before cytoreductive surgery showing that
the pelvic tumor has become larger (16.0 cm 12.4 cm). (C, D) Photomicrographs of the original uterine tumor showing patterns of sex-cord-like elements inﬁltrating the uterine
myometrium (H&E; 40). (E) Tumor cells with scant eosinophilia arranged in anastomosing trabeculae (H&E; 200). (F) Tumor cells with abundant cytoplasm arranged in small
nests (H&E; 200). CT¼computed tomography; H&E¼ hematoxylin and eosin.
Table 1
Cases of recurrent Group II uterine tumors resembling ovarian sex-cord tumors reported in the literature.
Author Age (y) Primary uterine tumor Period from hysterectomy
to recurrence
Recurrent site Recurrent tumor Treatment for recurrent tumor
Biermann et al [4] 68 ER: positive, PR:
positive, Ki-67: < 5%
4 y Abdominal cavity ER: positive, PR:
positive, Ki-67: 10%
Surgery
O'Meara et al [5] 35 ER: positive, PR:
positive, Ki-67: < 5%








Endo et al (present case) 62 ER: positive, PR:
positive, Ki-67: < 5%
23 y Pelvic lymph node ER: positive, PR:
positive, Ki-67: 15%
Hormonal therapy & surgery
ER, estrogen receptor; PR, progesterone receptor.
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UTROSCTs should undergo long-term follow-up. Conservative
treatment, including hormone therapy, may be ineffective for
recurrent tumors.Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this
article.
D. Endo et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 751e753 753References
[1] Clement PB, Scully RE. Uterine tumors resembling ovarian sex-cord tumors. A
clinicopathologic analysis of fourteen cases. Am J Clin Pathol 1976;66:512e25.
[2] Kantelip B, Cloup N, Dechelotte P. Uterine tumor resembling ovarian sex cord
tumors: report of a case with ultrastructural study. Hum Pathol 1986;17:
91e4.[3] Umeda S, Tateno M, Miyagi E, Sakurai K, Tanaka R, Tateishi Y, et al. Uterine
tumors resembling ovarian sex cord tumors (UTROSCT) with metastasis: clin-
icopathological study of two cases. Int J Clin Exp Pathol 2014;7:1051e9.
[4] Biermann K, Heukamp LC, Buttner R, Zhou H. Uterine tumor resembling ovarian
sex cord tumor associated with metastasis. Int J Gynecol Pathol 2008;27:58e60.
[5] O'Meara AC, Giger OT, Kurrer M, Schaer G. Case report: recurrence of a uterine
tumor resembling ovarian sex-cord tumor. Gyneol Oncol 2009;114:140e2.
